The MYCN gene belongs to the MYC gene family whose most prominent members include MYC, MYCN and MYCL. All three genes encode transcription factors represented as nuclear phosphoproteins with a short half-life of 20 ± 30 min (reviewed in Henriksson and LuÈ scher, 1996) . Common features of the Myc proteins are an N-terminal transactivation domain and a C-terminal basic region (b) helix-loop-helix (HLH) leucine-zipper (Zip) motif. The transactivation domain contains two short stretches of amino acids, the Myc boxes 1 and 2, which are highly conserved among Myc family proteins as well as between species (Ingvarsson, 1990; Schwab, 1988) . The basic region binds DNA with the E-box sequence CAC GTG as the recognition site (Blackwell et al., 1990; Prendergast and Zi, 1991; Kerkho et al., 1991) . The HLH-Zip motif mediates binding to the Max protein which, like Myc proteins, is a bHLH-Zip protein (Blackwood and Eisenman, 1991; Wenzel et al., 1991; Blackwood et al., 1992) . In contrast to Max, Myc family proteins cannot homodimerize under physiological conditions. Both in yeast and mammalian cells Myc/Max complexes activate transcription of reporter genes in an E-box dependent manner, whereas Max homodimers repress transcription (Amati et al., 1992; Kretzner et al., 1992; Amin et al., 1993; Gu et al., 1993) . Additional interaction partners of Max include the Mad family proteins Mad1, Mxi1, Mad3 and Mad4, which all contain the bHLHZip motif (Ayer et al., 1993; Zervos et al., 1993; Hurlin et al., 1995) . They heterodimerize with Max but are unable to homodimerize. Max/Mad1 and Max/Mxi1 heterodimers bind to the same E-box motif as the Myc/Max complexes, but in contrast, repress transcription (Cerni et al., 1995) . All these proteins are part of the Myc protein network that is presumably involved in regulating the transcription of Myc target genes (reviewed in Henriksson and LuÈ scher, 1996; Schreiber-Agus and DePinho, 1998) .
The MYC gene is expressed in nearly all human and fetal tissues. Mechanisms of deregulation in tumours include chromosomal translocation, such as in Burkitt's lymphomas (Khanna et al., 1995) , proviral insertion (DePinho et al., 1991) and gene ampli®cation (Schwab, 1998) . In contrast to the ubiquitous expressed MYC, MYCN gene expression has been seen preferentially in tissues of neuroectodermal origin. MYCN expression is high during early embryonic development and declines at later stages (Zimmerman et al., 1986) . MYCN is highly expressed consequent to gene ampli®cation, such as in neuroblastoma (Schwab et al., 1983 (Schwab et al., , 1984 , retinoblastoma (Lee et al., 1984) and small-cell lung cancer . Overexpression of MYCN is also the result of insertion of a Moloney leukemia provirus in the vicinity of MYCN (in T cell lymphomas) (van Lohuizen et al., 1989) .
Myc can regulate the expression of dierent genes. Some are activated by the Myc/Max complex in an Ebox-dependent manner (reviewed in Grandori and Eisenman, 1998) , such as a-prothymosin (Gaubatz et al., 1994) or ornithine decarboxylase (ODC) . Others are repressed by Myc through a mechanism that does not involve the Max protein (reviewed in Facchini and Penn, 1998) . Myc is not essential for cell growth. Rat ®broblast cell lines lacking c-myc due to knock-out continue to grow, although the growth rate is reduced to one third of their wild type parent (Mateyak et al., 1997) . Expression of nearly all proposed Myc target genes is unchanged in these cells, except for the cad gene and the growth arrest gene gadd 45 (Bush et al., 1998) .
In addition to Max, several proteins that interact with Myc have been identi®ed. Miz-1 (Peukert et al., 1997) , AP-2 (Gaubatz et al., 1995) , YY1 (Shrivastava et al., 1996) and BRCA1 (Wang et al., 1998) bind in vitro and in vivo to the C-terminal part, whereas atubulin (Alexandrova et al., 1995) , TBP (Maheswaran et al., 1994) , BIN1 (Sakamuro et al., 1996) , p107 (Gu et al., 1994; Beijersbergen et al., 1994) and TRRAP (McMahon et al., 1998) interact both in vitro and in vivo with the N-terminal region. Besides Max only Nmi has been described to bind to both Myc and MycN (Bao and Zervos, 1996) . Furthermore, Max and Nmi are the only known interaction partners of MycN that bind both in vitro and in vivo. In addition Nmi interacts with Max, Fos and daughterless in the yeast two-hybrid system (Bao and Zervos, 1996) .
Nmi mRNA is expressed dierentially in adult and fetal tissues, but was not detected in fetal or adult brain. Nmi expression is upregulated in some cancer cell lines with elevated MYC expression (Bao and Zervos, 1996) , and Nmi protein has been detected in several fetal tissues except for brain (Lebrun et al., 1998) . Interferon a (INFa), interferon g (INFg) and interleukin-2 (IL-2) upregulate Nmi expression. Immuno¯uorescence studies have demonstrated that Nmi is localized in the cytoplasm appearing in a punctate, granular pattern and that treatment with INFa results in accumulation of cytoplasmic Nmi. No Nmi was detected in cell nuclei (Lebrun et al., 1998) . Taken together, major portions of Myc proteins and of Nmi appear to be localized in dierent cellular compartments.
The Nmi protein interacts with six of seven signal transducer and activator of transcription (Stat) proteins. In response to IL-2 and INFg Nmi augments Stat-mediated transcription without having its own transactivation domain and enhances the association of CBP/p300 coactivator proteins with Stat5 and Stat1, respectively (Zhu et al., 1999 In order to identify interaction partners of the MycN protein we transfected yeast HF7c cells with a bait construct encoding a fusion protein of both the Gal4 DNA binding domain (Gal4 BD) and the central and C-terminal portion of the MycN protein encompassing amino acids 177 ± 456 (MycN-CT). Resulting cells were transfected with an EBV-transformed B cell library of cDNAs, fused to the Gal4 activation domain (Gal4 AD) (Durfee et al., 1993) . Screening of 1 million clones produced two clones coding for Max and 11 encoding the Nmi protein. Sequence analysis revealed that eight of the 11 clones contained the full length Nmi coding region. The remaining three clones encoded Nmi proteins with short N-terminal truncations of 6, 14 and 16 amino acids, respectively. In order to con®rm the interactions, full length and truncated clones were transfected together with the bait plasmids into yeast strain HF7c. Both, growing transfected yeast on SD/-trp/-leu/-his selection plates (lacking tryptophan, leucine and histidine) and b-galactosidase (bGal) ®lter assays con®rmed the interaction of MycN with full length as well as with N-terminally truncated Nmi proteins ( Figure 1A and data not shown). We conclude that the N-terminal 16 amino acids of the Nmi protein are not necessary for binding to MycN.
The speci®city of the MycN/Nmi interaction was evaluated by growth assays on SD/-trp/-leu/-his selection plates lacking tryptophan, leucine and (Bannasch and Schwab, 1999) . The Gal4 DNA binding domain (Gal4 BD(1 ± 147)) alone and a fusion protein of the Gal4 BD and p53 (p53 (72 ± 370)), which both do not interact with Nmi, served as negative controls. A fusion protein of the Gal4 BD and Max (Max (2 ± 160)) did not interact with Nmi. This is in contrast to the previously described interaction of Max with Nmi (Bao and Zervos, 1996) . All interactions were con®rmed by growth assays. Growth of transfected yeast on selection plates was observed only for bait proteins that also did interact with Nmi in the b-Gal assays (data not shown). As additional controls all bait constructs were employed together with (1) the empty Gal4 AD vector pACT, which encodes the Gal4 AD alone and (2) with pACT-YAF2 in b-Gal as well as in growth assays. pACT-YAF2 was isolated together with pACT-Nmi (clone 416) in the two-hybrid-screen. It encodes a fusion protein of the Gal4 AD and the YAF2 protein (YY1 associating factor 2; Kalenik et al., 1997) . None of the bait constructs did interact with In contrast to MycN both the central as well as the C-terminal region of Myc (Myc-CT1 and Myc-CT2) mediate interaction to the Nmi protein ( Figure 1C) . A shorter central part of Myc (Myc-CT1AB), however, does not bind to Nmi. Therefore at least a C-terminal region spanning amino acids 315 ± 439 of Myc is involved in Nmi binding ( Figure 1C) . A central region of Myc (aa 180 ± 251) might interact with Nmi as it is part of the larger Myc-CT1 fragment, which demonstrated interaction in the b-Gal assay ( Figure 1C ). Taken together, the main conclusion we draw from these data is that Myc and MycN proteins dier qualitatively in their binding capabilities to Nmi: the C-terminal portion of Myc interacts with Nmi, in contrast to the central portion of MycN.
Transactivation domains of mammalian transcription factors also have a transactivation potential in yeast. (Lech et al., 1988; Nerlov and Zi, 1995) . In order to investigate if the Nmi protein has a transactivation potential the Nmi cDNA insert of clone 416 was subcloned in frame with the Gal4 BD of pGBT9. This construct (pGNmi) was introduced into the yeast strain HF7c. Yeast cells were grown on a SD/-trp/-his selection plate lacking tryptophan and histidine and, as control, on a SD/-trp plate lacking only tryptophan. Transformants grew well on the SD/-trp plate but did not grow on the selection plate showing that the HIS3 reporter gene in HF7c could not be activated by Nmi (data not shown). Furthermore, a b-Gal ®lter assay demonstrated that the second reporter gene in HF7c, lac Z, also was not activated by Nmi (data not shown). As positive control both experiments were carried out with fusion proteins of the Gal4 BD and the N-terminal part of the MycN protein. HF7c yeast cells expressing fusions grew well on a SD/-trp/-his selection plate and turned blue in the b-Gal assay, demonstrating that the N-terminus of MycN has a strong transactivation potential in yeast (data not shown). We conclude that the Nmi protein has no transactivation potential in yeast and therefore alone is unlikely to act as a transcriptional activator in mammalian cells. This is in line with previously published data (Zhu et al., 1999) .
The subcellular localization of Nmi was determined by immuno¯uorescence analysis. The Nmi cDNA of clone 416 was fused in frame to the coding region of the enhanced green¯uorescent protein (EGFP) in vector pEGFP-C1 (ClonTech), resulting in plasmid pEGFPNmi. For control we used pEGFP-C1, which encodes the EGFP protein alone. pEGFP-C1 and pEGFP-Nmi were transfected transiently into 293 embryonic kidney cells, which do not express detectable amounts of MycN protein, and into Kelly neuroblastoma cells, which have large amounts of MycN (Wenzel et al., 1991) . The 293 Methods: Two-hybrid interaction was determined by employing b-Gal ®lter assays. Baits (left in (A ± C)) were constructed by fusing cDNA fragments or PCR products encoding the indicated proteins in frame to the Gal4 BD of pGBT9 (ClonTech). MycN-CT is a fusion protein of the Gal4 BD and the central and C-terminal region (aa 177 ± 456) of the MycN protein and is encoded by pGNMyc-CT. In order to identify MycN interacting proteins we performed a two-hybrid interaction screen (Fields and Song, 1989) and used MycN-CT as bait. Isolated clones included clone 416 (pACT-Nmi) which contains the complete coding region of the Nmi protein (Bao and Zervos, 1996) fused in frame to the Gal4 AD of pACT (Durfee et al., 1993 ) (ACT-Nmi). ACT-Nmi served as prey in the b-Gal assays. pGAD-Max encodes a fusion protein of the Gal4 AD and the Max protein (GADMax) and was constructed by insertion of the MAX cDNA in the Gal4 AD vector pGAD424. Details of the construction of all other clones are available on request. The identity of all constructs and isolated library clones was con®rmed by sequencing using an automated sequencer ABI Prism 310 (Applied Biosystems). b-Gal ®lter assays were performed using the indicated proteins (left in (A ± C)) as baits and ACT-Nmi as prey. pGBT9 and pGBT9 derivates were transfected separately together with clone 416 into the yeast strain HF7c (ClonTech). The only exception was the combination MycN-CT/GAD-Max in which the Nmi clone had been replaced by GAD-Max. The combination MycN-CT/GAD-Max represents the well studied interaction of MycN and Max (Wenzel et al., 1991; Bannasch and Schwab, 1999) and served as positive control in all b-Gal assays (data shown only in this ®gure (A)). The speci®city of Nmi was demonstrated by employing b-Gal assays with all bait proteins in combination with two other preys than pACT-Nmi, pACT and pACT-YAF2 (data not shown; but look at text). Transfected yeast cells were grown for 3 days at 308C on SD/-trp/-leu selection plates lacking tryptophan and leucine. Colonies were picked and incubated for 2 days in SD/-trp/-leu medium at 308C and 175 r.p.m. Subsequently 5 ml of these cultures were spotted regularly on ®lters (Whatman No. 1) which had been laid on fresh SD/-trp/-leu plates. After incubation for 2 days at 308C ®lters were lifted from the plates and b-Gal assays were performed (ClonTech protocol). Colour reactions were stopped after 3 h (A) or 6 h (B and C). All ®gures show typical results. Bait proteins are shown on the left.`b-Gal' indicates the results of the b-Gal assays. The intensity of the blue colour is a measure for the interaction strength that was de®ned as follows: +++++, very strong; ++++, strong; +++, moderate; ++, weak; +, very weak; 7, not detectable. and Kelly cells transfected with pEGFP-C1 revealed, as expected, both a nuclear and cytoplasmic staining of the EGFP protein (Figure 2Ab and 2Bc) . In contrast, cells transfected with pEGFP-Nmi showed exclusive staining of the cytoplasm, in part in a punctate, granular pattern (Figure 2Ae and 2Bg ). This cytoplasmic localization of Nmi is in line with previous observations (Lebrun et al., 1998 ) that had demonstrated a granular, cytoplasmic staining of Nmi in dierent cell lines using polyclonal anti-Nmi antibodies. Furthermore, by immunofluorescence using the same Nmi antiserum (anti-Nmi (1-67); kindly provided by L Naumovski; described in Lebrun et al., 1998) , we detected endogenous Nmi exclusively in the cytoplasm of Kelly cells stimulated with interferon g (INFg) (Figure 2Cc showed an exclusive cytoplasmic staining of EGFPNmi (Figure 2Bg ). Furthermore, in INFg treated Kelly cells endogenous Nmi was found exclusively in the cytoplasm (Figure 2Cc,d) . Taken together, our data clearly demonstrate that the vast majority of MycN and Nmi proteins is localized in dierent cellular compartments. Therefore in vivo at best a small portion of MycN and Nmi proteins, not detectable by immuno¯uorescence, is present as a complex. By employing the yeast two-hybrid system we here show that Nmi interacts with both MycN and Myc. Binding of Nmi to Max could not be detected. This result is in contrast to the previously described Nmi/ Max interaction detected with the Lex A two-hybrid system (Bao and Zervos, 1996) . A possible explanation for the dierent result could be that the Gal4 twohybrid system is more selective in detection of proteinprotein interactions than the Lex A two-hybrid system. We also found that Nmi, fused to the Gal4 BD, alone is not a transcription activator in yeast. In agreement with this is the observation that Nmi alone cannot activate transcription in mammalian cells (Zhu et al., 1999) suggesting that it lacks an intrinsic transactivation domain.
The C-terminal halves of MycN (aa 232 ± 456) and Myc (aa 265 ± 439) have been shown to mediate binding to Nmi (Bao and Zervos, 1996) . Our more precise mapping data demonstrate a dierence between C Figure 2 Nmi is localized in the cytoplasm of 293 and Kelly cells in a punctate granular pattern. The ®gures show typical results. Methods: The insert of Nmi clone 416 was cloned in frame to the coding region for the EGFP protein into plasmid pEGFP-C1 (ClonTech), resulting in pEGFP-Nmi. The identity of the construct was con®rmed by sequencing. 293 or Kelly cells were seeded on poly-lysine coated cover-slips, which were placed into 6-well dishes and were covered after 10 min with medium (RPMI containing 10% FCS, 100 units/ml penicillin, 100 mg/ml streptomycin and 0.2% amphotericin). Cells were incubated at 378C, 5% CO 2 until they had reached 50 ± 80% con¯uence. Then cells were washed once with medium, and 1.5 ml medium containing transfection-mix (150 ± 200 ml) was added to each well. (Transfection-mix: 0.4 mg of plasmid pEGFP-C1 or 0.4 mg of pEGFP-Nmi was mixed with 80 ml EC buer (QIAGEN); 1 ml enhancer (QIAGEN) was added, carefully mixed and after 10 min combined with a solution containing 80 ml EC buer and 3 ± 4 ml eectene transfection reagent (QIAGEN)). Cells were incubated for 24 ± 36 h at 378C, 5% CO 2 to allow expression of EGFP or EGFP-Nmi proteins. Then cells were washed twice with medium, ®xed in 3.7% formaldehyde in PBS for 10 min, washed three times with PBS and permeabilized in PBS containing 0.05% Nonidet P40 (Sigma) and 0.1% BSA. Subsequently cells were washed three times with PBS, incubated in 0.125 mg/ml 4' diamidino-2-phenylindole (DAPI) for 2 min to stain the nuclei and washed two times with PBS. Then cover-slips (cell-side down) were mounted on slides in antifade solution. Cells were analysed with a Zeiss Axiophot microscope combined with a FL4 ®lter-set (Zeiss). Images were taken with a cooled chargecoupled device camera (KAF 1400; Photometrics) and processed using IPLab Spectrum software. In (B) the DAPI stain was preceeded by detection of the MycN protein in Kelly cells. For each sample 50 ml PBS containing a 1 : 100 dilution of monoclonal anti-MycN antibody B8.4.B (Wenzel et al., 1991) was put in the wells of 6-well plates and immediately covered with the cover-slips (cell-side down). After a 1 h incubation at room temperature cells were washed three times with PBS and incubated subsequently in a 1 : 100 dilution of Cy3-conjugated sheep anti-mouse IgG (Dianova) in PBS/0.1% BSA for 1 h at room temperature in the dark. Then cells were washed three times with PBS and counterstained with DAPI. Transfected and not transfected Kelly cells, incubated with secondary antibody alone, served as negative controls and showed only background staining (data not shown). In (C) Kelly cells were not transfected, but stimulated with INFg. Cells were grown for 40 h on cover-slips in RPMI medium containing 10% FCS and 500 u/ml INFg. MycN and Nmi were detected simultanously by double colour immuno¯uorescence. For detection of MycN and Nmi cells were treated as in (B) with the following changes: each sample was incubated with a mix of a 1 : 500 dilution of anti-MycN antibody B8.4.B and a 1 : 1000 dilution of polyclonal Nmi antiserum (anti-Nmi (1 ± 67); Lebrun et al., 1998) in 50 ml PBS for 1 h at room temperature. Cells were washed three times with PBS and then incubated in 50 ml PBS containing a mix of a 1 : 50 dilution of¯uorescein (FITC) conjugated goat anti-mouse IgG (Dianova) to detect the MycN signal and a 1 : 100 dilution of Cy3 conjugated goat anti-rabbit IgG ( MycN and Myc interaction domains: in MycN a central region (aa 177 ± 298) is exclusively responsible for binding to Nmi, in contrast to the involvement of a C-terminal part in Myc (aa 315 ± 439). Whether a small central region of Myc (aa 180 ± 251) could also mediate binding to Nmi has to be tested in future studies.
MycN is the ®rst member of the Myc family for which a central part is involved in protein-protein interactions. Myc/Nmi interaction involves the Cterminal part of Myc including the HLH-Zip motif that is necessary for heterodimerization with the Max protein (Blackwood and Eisenman, 1991 Nmi is also an interaction partner of known Stat proteins, except Stat2 (Zhu et al., 1999) . Two regions of Nmi, corresponding to residues 57 ± 99 and 143 ± 202 are responsible for binding to Stat5b (Zhu et al., 1999) . Whether the same regions of Nmi also mediate binding to MycN and Myc remains to be determined in future studies. Kelly neuroblastoma cells express high level of MycN consequent to an about 100-fold ampli®cation of the MYCN gene (Wenzel et al., 1991) . Our immuno¯uorescence studies show that in Kelly cells ectopically expressed EGFP-Nmi as well as endogenous Nmi (which is expressed only after stimulation of Kelly cells with INFg) is detected only in the cytoplasm. In contrast, MycN appears localized exclusively in the nuclei of the same pEGFP-Nmi transfected cells as well as in the nuclei of pEGFP transfected and not transfected Kelly cells. In addition, INFg stimulated Kelly cells also show exclusively nuclear MycN. This demonstrates that the vast majority of MycN and Nmi is localized in dierent cellular compartments, independent of Nmi being expressed either ectopically or endogenously. If MycN interacts with Nmi it must be expected that at least a part of MycN and Nmi is localized in the same cellular compartment, either in the cytoplasm or in the nuclei of Kelly cells. It is possible that a small portion of MycN and Nmi is localized in the same cellular compartment but remains undetectable by immunouorescence.
Immuno¯uorescence of three dierent cell lines has shown that Nmi is localized in the cytoplasm (Lebrun et al., 1998) . Nmi was not detected in the nuclei. Cells which express elevated levels of Nmi protein after induction with INFa also showed no nuclear Nmi localization (Lebrun et al., 1998) . These results are in line with the immun¯uorescence data presented in this study. Cell fractionation demonstrated that after treatment of Jurkat cells with INFa the Nmi protein is found in part in the nuclear fraction. Cell fractionation of untreated cells, however, revealed Nmi almost exclusively cytoplasmic (Lebrun et al., 1998) . Collectively these results suggest that Nmi is predominantly cytoplasmic. The localization of Myc or MycN proteins was not studied in the experiments of Lebrun et al., 1998, however. Nmi is capable of increasing IL-2 and INFg induced Stat-dependent transcription from a reporter construct in mammalian cells and enhances recruitment of CBP/ p300 coactivators to Stat5 (or Stat1) (Zhu et al., 1999) . This indicates that Nmi plays an important role in modulating Stat mediated transcription. The coprecipitation of Nmi in a complex with CBP and Stat5 or Stat1 as well as Nmi mediated enhancement of Stat5-dependent transcription in cooperation with CBP argue for a nuclear localization of at least a part of Nmi proteins. Therefore, it is likely that Nmi is translocated into the nucleus after cytokine treatment. This conclusion is supported by the detection of nuclear Nmi by cell fractionation of INFa treated Jurkat cells (Lebrun et al., 1998) . However, Nmi was not detected in nuclei of INFa or INFg treated cells by immunouorescence analysis (Lebrun et al., 1998 , and this study). Our immuno¯uorescence analyses have shown that ectopically expressed EGFP-Nmi protein as well as endogenous Nmi is detected only in the cytoplasm. It is possible that under certain physiological conditions, such as cytokine treatment of cells, a portion of Nmi is translocated into the nuclei where it could play a role as modulator of Myc/MycN dependent transcription, similar to the modulation of Stat protein-mediated transcription (Zhu et al., 1999) .
An alternate possibility is that MycN would be, in part, translocated to the cytoplasm where it interacts with Nmi. Previous studies have shown that MycN is cytoplasmic in spinal ganglion neurons of 12.5-day-old mouse embryos as well as in spinal and retinal ganglion neurons of more than 10-day-old chicken embryos (Wakamatsu et al., 1993) . In spinal ganglia of younger embryos MycN is nuclear in all cells. A cytoplasmic MycN/Nmi complex could be involved in signal transduction. Also, Myc could interact with Nmi in the cytoplasm because Myc is cytoplasmic when it interacts with a-tubulin (Alexandrova et al., 1995) .
Taken together, we have shown that MycN and Myc regions involved in binding to Nmi dier. In the neuroblastoma cell line Kelly all detectable Nmi is cytoplasmic, in contrast to the seemingly exclusive nuclear localization of MycN. Further studies will show under which physiological conditions, and in which cellular compartment, MycN and/or Myc proteins may interact functionally with Nmi.
